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List of abbreviations: 
 
18FDG-PET: 18Fluor-deoxyglucose-positron emission tomography  
CEA: carcinoembryonic antigen 
EGFR: epidermal growth factor receptor 
EMA: epithelial membrane antigen  
EPP: extrapleural pleuro-pneumonectomy  
Glut1: glucose transporter 1 
HGFR: hepatocyte growth factor receptor 
Hif1: hypoxia inducible factor 1 
Hif2: hypoxia inducible factor 2 
IMIG: International Mesothelioma Interest Group 
LDH: lactate dehydrogenase 
MAP-kinase: mitogen-activated protein kinase 
MPM: malignant pleural mesothelioma 
mTOR: mammalian target of Rapamycin 
NF2:  neurofibromin 2 
PDK: pyruvate dehydrogenase kinase 
PHD: prolyl hydroxylases 
PI3K: phosphoinositide-3-kinase 
pVHL: von Hippel-Lindau protein 
RAS: rat sarcoma 
TCA: tricarboxylic acid 
TMA: tissue micro array 
TTF-1: thyroid transcription factor 1 
VEGF: vascular endothelial growth factor 
WT1: Wilms tumor protein 1 
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1. Abstract 
 
Background: Malignant pleural mesothelioma (MPM) is a therapy refractory 
tumor of the pleural lining mesothelial cells. As of today not much is known 
about the molecular pathology of MPM. The hypoxia inducible factors (Hif) 
have been implicated in the pathogenesis of many solid tumors. Its 
stabilization leads to a glycolytic phenotype and angiogenesis, two hallmarks 
of cancer. This study aimed to identify a correlation between expression of 
Hif1 and one of its target genes glucose transporter 1 (Glut1) with survival of 
MPM patients. 
Patients and Methods: Between 1999 and 2009 a prospective patient cohort 
containing 192 patients diagnosed with MPM was investigated on tissue micro 
arrays (TMA) by immunohistochemistry. Four TMAs were constructed, two 
with pre-chemotherapy biopsies and another two with corresponding tissue 
from the post-chemotherapy extrapleural pleuro-pneumonectomy (EPP) or 
decortication and debulking specimens, respectively. Nuclear Hif1 and 
membranous Glut1 immunoreactivity was scored semi-quantitatively. The 
patients were divided into two groups according to there average score, one 
group with no/very low protein levels and one group with medium/high protein 
expression. These two groups were then statistically analyzed for overall 
survival, tumor stage and histology. 
Results: 140 patients could be analyzed from the pre- and 141 from the post- 
chemotherapy TMAs. In the pre-chemotherapy samples the survival time was 
correlated to Hif1 expression. Comparing any Hif1 expression to no 
expression, median survival was significantly shorter (log rank test p=0.025). 
This association could not be found in the post-chemotherapy samples 
(p=0.59). For the Glut1 expression there was a trend visible towards shorter 
survival of the patients with higher protein levels, however there was no 
statistical significance (log rank test pre-chemotherapy samples p=0.19 and 
for post-chemotherapy samples p=0.06). The more advanced tumor stages 
showed higher expression of Glut1 (Chi-square test p=0.027 for T stage and 
p=0.012 for IMIG stage respectively). A similar correlation could not be 
observed for Hif1. 
Conclusion: This thesis adds to the evidence that the expression of Hif1 
and the glycolytic phenotype could play an important role in the progression of 
MPM. Concerning survival, high expression of Hif and Glut1 may be 
associated with shorter survival, although significance of these results may be 
influenced by the neo-adjuvant chemotherapy preceeding surgery.  
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2. Introduction 
 
Malignant pleural mesothelioma (MPM) is an aggressive and therapy resistant 
tumor of the mesothelial cells lining the pleural cavity, which increases in 
frequency throughout the world. In the canton of Zurich 30 new cases are 
diagnosed every year with an incidence of 3.7/100000 in men and 0.6/100000 
in women (Ceschi et al., 2009). With a 5-year survival rate of 10,3% the 
prognosis is still very poor (diagnosis 1995-99). The majority of the patients 
have a history of occupational asbestos exposure (Ceschi et al., 2009). 
Patients with mesotheliomas typically present with pleural effusion, which is 
often associated with chest wall pain. B-symptoms like fatigue or weight loss 
can also be present. Occasionally, patients have no symptoms and the 
disease is diagnosed on a routine chest radiograph (Robinson et al., 2005).  
There are three different histologic subtypes of mesotheliomas: Epithelioid 
mesothelioma resembling tissue of epithelial origin, sarcomatoid 
mesothelioma with a spindle cell character and biphasic mesothelioma with 
parts of both types (Figure 3).  The epithelioid type accounts for approximately 
60%, sarcomatoid for 20% and biphasic ranges around 20% of all 
mesotheliomas (Sekido, 2010). The morphological diagnosis of pleural 
mesothelioma is generally made by a pleural biopsy, preferentially by 
thoracoscopy. To distinguish between lung adenocarcinoma and epithelioid 
mesothelioma immunohistochemistry is important. Markers for an epithelioid 
mesothelioma are calretinin, D2-40, Wilms tumor protein 1 (WT1), cytokeratin 
5/6 and podoplanin, while carcino-embryonic antigen (CEA), epithelial 
membrane antigen (EMA) and thyroid transcription factor 1 (TTF-1) are 
markers for the diagnosis of adenocarcinoma and are almost never expressed 
in malignant mesothelioma. As of today there is no standard therapy for 
patients with malignant pleural mesothelioma. However a multicenter study 
conducted in Switzerland including neoadjuvant chemotherapy with 
cisplatin/gemcitabine or cisplatin/pemetrexed followed by extrapleural pleuro-
pneumonectomy (EPP) showed good results compared to historical outcomes 
(Weder, 2010).  
The molecular pathology of malignant pleural mesothelioma has an unusual 
pattern with predominant loss of tumor suppressor genes, especially the 
p14INK4A, p16ARF, and neurofibromin 2 (NF2) genes. Well-known oncogenes 
like rat-sarcoma (RAS) or phosphoinositide-3-kinase (PI3K) are not frequently 
mutated. However activation of the upstream receptor tyrosine kinases 
including the family of epidermal growth factor receptors (EGFR) or 
hepatocyte growth factor receptor (HGFR) with subsequent activation of 
mitogen-activated protein  (MAP) kinase and PI3K signaling cascades are 
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frequently identified in mesothelioma cells (Sekido, 2010). For an overview of 
oncogenic signaling through receptor tyrosine kinases see Figure 1. 
 
 
 
 
Figure 1: (Herbst et al., 2008) Oncogenic signaling through the EGFR 
receptor: In normal cells EGFR is activated through binding of a growth factor 
ligand. This binding leads to a dimerization of EGFR and thereby to an 
activation of the downstream signaling pathways like the MAP-Kinase or the 
PI3-Kinase pathway, which leads to cell survival and proliferation. In cancer 
cells a point mutation in a gene encoding one of this signaling proteins can 
lead to a constitutive activation of the signaling cascade. This leads to 
uncontrolled proliferation of the cell and can contribute to other hallmarks of 
cancer like angiogenesis, invasion and metastasis. 
 
Hypoxia inducible factor 1 (Hif1) is a transcription factor that is activated 
upon low tissue oxygenation. In normoxia Hif1 is hydroxylated on proline 
residue 402 and/or 564 by prolyl hydroxylases (PHD). This modification leads 
to the binding of the von Hippel-Lindau (pVHL) E3 ligase complex and to the 
subsequent ubiquitination and proteasomal degradation of Hif1 (Wang et al., 
1995). During hypoxia stable Hif1 heterodimerizes with Hif1 (also known as 
aryl hydrocarbon receptor nuclear translocator protein, ARNT) and is imported 
into the nucleus, where it leads to the transcription of glycolytic genes 
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(pyruvate dehydrogenase kinase (PDK), lactate dehydrogenase (LDH) and 
glucose transporter 1 (Glut1) as well as to the induction of angiogenesis via 
expression of vascular endothelial growth factor (VEGF) (Semenza, 2010). 
During cancer progression rapid proliferation of cancer cells often outgrow 
blood supply. This leads to low oxygen concentration in the tumor tissue and 
to an up-regulation of Hif1. Immunohistochemical analysis of human cancer 
biopsies showed increased levels of Hif1 protein in the majority of primary 
human cancers and their metastases (Zhong et al., 1999). It has been shown 
that increased levels of Hif1 expression, determined by 
immunohistochemistry not only is associated with increased patient mortality 
in a variety of human cancers but also correlates with chemo- and 
radiotherapy resistance (see Semenza 2010 for an overview of the literature). 
Loss of function of many tumor suppressors leads to a stabilization of the 
Hif1 protein. The most famous example is loss of VHL protein in clear cell 
renal cell cancer. This leads to constantly activated Hif1 and thereby to 
increased angiogenesis and a glycolytic phenotype (Maxwell et al., 1999). It 
was demonstrated that other factors apart from oxygen like iron (Fe), 
ascorbate, and various tricarboxylic acid (TCA) cycle intermediates can affect 
proline hydroxylase activity (Pan et al., 2007) (see Figure 2) Activation of 
oncogenic signaling through the PI3K/AKT or MAP-Kinase pathway also 
increases Hif1 synthesis through the activation of mammalian target of 
Rapamycin (mTOR) (Laughner et al., 2001). 
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Figure 2: (Haase, 2006) Hif1 is a very unstable protein. Under normoxic 
conditions it is constantly ubiquitinated via the pVHL-E3-ubiquitin ligase 
complex and degraded by the proteasome. Under low oxygen concentrations 
Hif1 is stabilized and can translocate to the nucleus, where it leads to the 
transcription of its target genes. For pVHL binding Hif1 has to be 
hydroxylated on proline residues. For this reaction cofactors like reduced iron 
(Fe2+) and the TCA intermediate -ketoglutarate are necessary. 
 
Glucose transporter 1 (Glut1) is one of the most important target genes of 
Hif1. Glut1 is expressed in almost all human tissues and takes up glucose 
into the cell in an Insulin-independent way. Already in 1930 Otto Warburg 
described an up-regulated glycolytic activity in cancer (Warburg, 1956). This 
phenomenon of elevated glycolysis even in the presence of oxygen is known 
as the ‘Warburg effect’. Nowadays the elevated glucose consumption rate of 
cancer is used in 18FDG-PET for diagnostic purposes and can be seen as a 
hallmark of cancer (Hanahan and Weinberg, 2011). The fact that the glycolytic 
phenotype in primary and metastatic cancers persists also in the presence of 
oxygen indicates that it confers a selective growth advantage to the cancer 
cell. It has been shown that oncogenic up-regulation of the PI3K/AKT and 
mTOR/S6K pathway leads to increased glycolysis and glucose consumption 
(reviewed in Gatenby and Gillies, 2004). 
Gene expression profiling of mesothelioma tissue specimens from 16 patients 
and 4 control samples by cDNA microarray showed the most significant up-
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regulation in glycolytic genes. Lactate dehydrogenase (LDH) was up-
regulated 5-fold and there was a strong and significant positive correlation 
with Hif1 levels (r2=0.98, Spearman coefficient, P < 0.05). This suggests a 
role for Hif1 in the pathogenesis of malignant pleural mesothelioma (Singhal 
et al., 2003). It was shown that a 24h incubation of mesothelioma cells with 
crocidolite asbestos fibres leads to an activation of Hif1 and to a reduced 
sensitivity to doxorubicin treatment. It was proposed that crocidolite leads to 
an iron chelation at the fibre surface and decreases iron availability in the 
cells, a situation that would  subsequently give rise to an activation of Hif1 
(Riganti et al., 2008). In a small study with 34 specimens from patients with 
malignant pleural mesothelioma it was shown that Hif1 is commonly 
expressed in the tumor tissue but not in normal mesothelium. However the 
authors could not show a statistically significant effect of Hif1 expression on 
prognosis of patient survival (Klabatsa et al., 2006). 
There is a lot of evidence for a role of Hif1 levels and the emerging glycolytic 
phenotype in the pathogenesis of malignant pleural mesothelioma. Until now 
there is no study published on a large patient collective about the prognostic 
significance of Hif1 and Glut1 protein expression levels. For this purpose a 
tissue microarray with tissue specimens from approximately 200 patients with 
pre- and post-chemotherapy samples was constructed.  
The aim of this thesis is to study the correlation of Hif1 as well as Glut1 
protein expression levels with patient survival, using the tissue microarray 
technology. 
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A      B 
  
C      D 
  
E  
Figure 3: Histologic subtypes 
epithelioid mesothelioma A 
10x; B 40x; sarcomatoid 
mesothelioma C 10x, D 40x; 
biphasic mesothelioma E 10x 
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3. Patients and methods 
3.1 Patients and tissue collection 
 
For the time period of 1999 to 2009 a total of 192 patients with malignant 
pleural mesothelioma diagnosed by thoracoscopy were investigated. Once 
diagnosed the patients were assigned to the University Hospital of Zurich, 
were they received neoadjuvant chemotherapy and most of them (147) 
underwent extrapleural pleuro-pneumonectomy, decortication or debulking 
thereafter. For the pre-chemotherapy analysis 52 of the patients were 
excluded because of lack of material. From the 147 patients that underwent 
post-chemotherapy surgery 6 were excluded because of insufficient material. 
Additional information such as age, gender and staging were gathered from 
pathology reports. Pathological staging was done as recommended by the 
IMIG (International Mesothelioma Interest Group) staging system (see Table 
2) (Wittekind et al., 2010). Staging was available from 153 patients. Survival 
and follow-up data was gathered from the reports of the Thoracic Surgery 
department. The average patient age was 61 and ranged form 35 to 93. 
Twenty patients were female and 172 male. An overview of the pathological 
and clinical parameters as well as hospitals of first diagnosis can be found in 
Table 1. 
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Table 1: Pathological and clinical parameters 
 
      tissue sample 
   n       % 
Total 192 100 
 
Hospital diagnosed Universitätsspital Zürich 121 63 
 Stadtspital Triemli    8  4 
 Kantonsspital Luzern    6  3 
 Kantonsspital Winterthur   15  8 
 Kantonsspital Aarau    6  3 
 Kantonsspital Baden    7  4 
 Kantonsspital Graubünden    2  1 
 Kantonsspital St. Gallen    5  3 
 Universitätsspital Basel    3  2 
 Inselspital Bern     4  2 
 Kantonsspital Münsterlingen   11  6 
 others    4  2 
 
Histology epithelioid 102 53 
 sarkomatoid  8  4 
 biphasic 51 27 
 
Tumor stage pT1  11  8 
 pT2  53 40 
 pT3  56 43 
 pT4  11  8 
 
Nodal status pNx  1  1 
 pN0  83 63 
 pN1  18 14 
 pN2  29 22 
 pN3   0  0 
 
Metastases pMx  66 50 
 pM0  64 49 
 pM1    1  1 
 
IMIG stage I 11  7 
 II 31 20 
 III 79 52 
 IV 32 21 
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Table 2: IMIG staging system for malignant pleural mesothelioma  
 
Primary tumor (T): 
 T1: Tumor involves pleura parietalis of same side (T1b + focal 
involvement of pleura visceralis). 
 T2: Tumor involves same side pleura with at least one of the following 
features: Confluent tumor on pleura visceralis, involvement of the 
muscles of the diaphragm or the lung tissue deeper to the mesothelium 
covering the lung. 
 T3: Involvement of the endothoracic fascia, the mediastinal fat or single 
focus of tumor involving the soft tissue of the chest wall   
 T4: Invasion of any mediastinal organ, diffuse or multi-focal 
involvement of the soft tissue of the chest wall, rib, peritoneum, pleura 
of the other site, malignant pericardial effusion or involvement of heart 
muscle 
Lymph node involvement (N): 
 N0: No regional lymph node involvement 
 N1: Involvement of same side bronho-pulmonary and or hilar lymph 
nodes only  
 N2: Involvement of subcarinal lymph node(s), and or same side or 
opposite side internal mammary or mediastinal lymph node(s) 
 N3: Involvement of opposite side mediastinal, internal mammary, or 
hilar lymph node(s) and or same side or opposite side supraclavicular 
or scalene lymph node(s) 
  
Distant metastasis (M): 
 Mx: Distant metastasis cannot be assessed  
 M0: No distant metastasis  
 M1: Distant metastasis present  
 
IMIG-Stage: 
Stage I: T1 N0 M0 (Stage IA: T1a N0 M0, Stage IB: T1b N0 M0) 
Stage II: T2 N0 M0 
Stage III: T1, T2 N1 M0 or T1, T2 N2 M0 or T3 N0, N1, N2, M0 
Stage IV: T4 any N M0 or any T N3 M0 or any T any N, M1 
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3.2 Construction of TMA    
 
Four tissue microarrays (TMA) were constructed according to an established 
method (Kononen et al., 1998). Hematoxylin-Eosin stained sections of 
thoracoscopic biopsies and surgical speciments were reviewed and 
representative areas were selected. Tissue cylinders with a diameter of 0.6 
mm were punched out from those areas of the corresponding paraffin blocks. 
We constructed 2 TMAs from the thoracoscopic biopsies with 2 tissue 
cylinders per patient as well as 2 TMAs from surgical specimens with 4 tissue 
cylinders per patient sample. Additionally, on the 2 surgical specimen TMAs 
20 punches of different control tissues, including normal mesothelium, 
adenocarcinoma of the lung, lymphoid tissue and 4 different mesothelioma 
cell lines were collected. With the help of an automatic tissue arrayer 
(Beecher Instruments, Sun Prairie, WI, USA) the TMAs were constructed by 
precisely arraying the tissue cylinders in a new paraffin block. Figure 4 shows 
the device and an example of a TMA.  
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A 
 
 
B 
 Figure 4: A: Tissue array device for the construction of the TMA. B: 
Overview of the tissue microarray block. 
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3.3 Immunohistochemistry 
 
For immunohistochemical analysis, 4-m-thick paraffin sections were cut from 
the TMA block and mounted on silane coated glass slides. After incubation at 
37°C overnight, deparaffinization in xylene and rehydration through graded 
ethanol series were performed. For the Glut1 staining the rabbit polyclonal 
antibody AB1341 (Chemicon/Millipore Corporation) was used at a 1:1000 
dilution on a Ventana Benchmark® platform (Ventana Medical Systems, 
Tucson, AZ, USA), the cell conditioner 1 (CC1) standard mono protocol (CC1-
mono) was performed: pre-treatment with boiling for 60 min in pH 8 Tris 
buffer, incubation with primary ab for 60 min at room temperature (RT) and 
development with the Ultraview- HRP mono kit, including incubation with 
respective secondary ab for 30 min at RT. For Hif1 a mouse monoclonal 
antibody (Abcam, Cambridge UK) was used in a 1:400 dilution on a Leica 
Bond® platform (Vision Biosystems, Melbourne, Australia), the H2 standard 
(H2-60) protocol was performed: pre-treatment with boiling for 60 min in pH 8 
Tris buffer, incubation with primary ab for 30 min at RT. 
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3.4 Interpretation of results 
 
For each core the intensity of immunoreactivity was scored semiquantitatively. 
For Hif1 nuclear staining was scored from 0 to 3 (0=no staining, 1=weak 
staining, 2=moderate staining, 3=strong staining). Glut1 scoring was 
performed for intensity and frequency. Intensity was scored the same way like 
for Hif1, frequency was scored as a percentage of stained cancer cells 
(0%=0, 1-9%=0.1, 10-49%=0.5, 50-100%=1). Out of this two scores an H-
score was calculated as intensity multiplied with frequency. Figure 5 shows 
examples of weak and strong staining of Hif1 and Glut1 samples. 
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A      B 
 
  
C      D 
  
Figure 5: Hif1 staining: A: no; B: 
strong; Glut1 staining: C: no; D: strong 
10x 
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3.4 Statistical analysis 
 
The correlation between clinicopathological findings and immunohisto-
chemical parameters was calculated by Chi-squared tests.  
For all investigations with respect to patient prognosis, the overall survival 
was chosen as the endpoint. For calculation of the survival time, living 
patients were evaluated as "censored". 
The illustration of the cumulative survival curves was performed by the 
method of Kaplan-Meier. A log rank test was used for the statistical 
assessment of differences between cumulative survival curves. Statistical 
analyses were performed using the statistical software package SPSS-
statistics 19 (SPSS Inc., Chicago, IL, USA). P-values < 0.05 were considered 
statistically significant in all analyses. 
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4. Results 
4.1 Overall and median survival 
 
There was a significant association between IMIG-Stage and overall survival 
rates (p=0.013). Figure 6 shows the survival curves for the IMIG-Stages. 
The median survival rates were very poor with an estimate of 22 month for all 
patients and respective median survival rates of 40 month in Stage I, 26 
month in Stage II, 21.5 month in Stage III and 11.5 month in Stage IV 
patients. 
 
 
 
Figure 6: IMIG-Stage and Overall survival 
 
  
p=0.013
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4.2 Immunohistochemical findings 
 
In order to evaluate the correlation of protein expression and survival rates the 
results obtained from TMA scoring for Hif1 and Glut1 were divided into two 
equal groups (no/low expression and moderate/strong) and compared with 
the survival rates of the patients. The pre- and post-chemotherapy results 
were analysed independently.  
 
 
4.2.1 Hif1 
4.2.1.1 Pre-chemotherapy samples 
 
From the 140 analysed patients from the pre-chemotherapy samples 83 had 
no immunohistochemical detectable Hif1 protein. The survival of these 
patients was compared to the 57 with Hif1 expression. Overall survival of the 
patients with no Hif1 expression was significantly longer than that of the 
patients with Hif1 expression (p=0.025). There was no association with 
tumor histology detectable. 
 
 
 
Table 3: Mean Hif1 score in pre-chemotherapy samples 
 
Hif1 mean score Total N N of Events 
Censored 
N Percent 
= 0 83 70 13 15.7% 
1-3 57 48 9 15.8% 
Overall 140 118 22 15.7% 
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Figure 7: Hif1 expression in pre-chemotherapy samples and overall survival 
 
 
 
4.2.1.2 Post-chemotherapy samples 
 
In the post chemotherapy samples from the 141 analysed, 82 had an 
average staining of less than 0.5 and 59 patients had a staining of more than 
0.5. There was no statistically significant difference in overall survival 
between these two groups (p=0.59). There was a statistically significant 
correlation towards less Hif1 expression in sarcomatoid and biphasic 
mesothelioma as well as higher tumor stages. For IMIG stage there was no 
statistically significance but also a trend to less Hif1 expression in 
advanced stages (Table 5).   
  
p=0.025
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Table 4: Mean Hif1 score in post-chemotherapy samples 
 
Hif1 mean score Total N N of Events 
Censored 
N Percent 
</= 0.5 82 72 10 12.2% 
>0.5 59 55 4 6.8% 
Overall 141 127 14 9.9% 
 
 
 
 
 
 
Figure 8: Hif1 expression in post-chemotherapy samples and overall survival 
 
  
p=0.59
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Table 5: Hif1 expression and histopathological parameters. 
 
       Hif1 expression 
       ≤0.5  >0.5 
      n n(%)  n(%) 
Histology  epithelioid  77 42(55%) 35 (45%)  
   sarcomatoid  8 5(62.5%) 3(37.5%) 
p=0.046  biphasic  56 35(62.5%) 21(37.5%) 
 
Tumor stage pT1   11 6(55%) 5(45%) 
   pT2   44 21(48%) 23(52%) 
   pT3   53 35(66%) 18(34%) 
p=0.042  pT4   20 12(60%) 8(40%) 
 
IMIG stage  1   10 6(60%) 4(40%) 
   2   29 13(45%) 16(55%) 
   3   71 45(63%) 26(37%) 
p=0.054  4   21 13(62%) 8(38%)  
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4.2.2 Glut1 
4.2.2.1 Pre-chemotherapy samples 
 
The 140 patients analysed for Glut1 expression were divided into two almost 
equal groups. 75 patient samples showed no or almost no 
immunohistochemicaly detectable expression of Glut1 (mean H score ≤0.3) 
and 65 patients showed some expression (mean H score >0.3). Between this 
two groups there was no statistically significant difference in overall survival 
(p=0.19). There was no association with tumor histology detectable. 
 
 
 
Table 6: Mean Glut1 H-score in pre-chemotherapy samples 
 
Glut1 mean H-score Total N N of Events 
Censored 
N Percent 
</= 0.3 75 63 12 16.0% 
>0.3 65 55 10 15.4% 
Overall 140 118 22 15.7% 
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Figure 9: Glut1 expression in pre-chemotherapy samples and overall survival 
 
 
4.2.2.2 Post-chemotherapy samples 
 
From the 141 patient samples analysed 78 had no detectable Glut1 staining 
and 63 had some Glut1 staining detectable (Table 7). There was no 
statistically significant difference in overall survival detectable between these 
two groups (p=0.06). But a Chi-square test showed a statistically significant 
correlation between Glut1 expression and tumor as well as IMIG stage with p-
values of 0.027 and 0.012 respectively (Table 8). No differences in Glut1 
expression between the histological subtypes could be detected. There was 
no correlation between Glut1 and Hif1 expression with a Pearson-coefficient 
of -0.123 (p=0.145). 
  
p=0.19
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Table 7: Mean Glut1 H-score in pre-chemotherapy samples 
 
Glut1 mean H-score Total N N of Events 
Censored 
N Percent 
= 0 78 71 7 9.0% 
1-3 63 56 7 11.1% 
Overall 141 127 14 9.9% 
 
 
 
 
 
Figure 10: Glut1 expression in post-chemotherapy samples and overall 
survival 
 
 
  
p=0.06
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Table 8: Glut1 expression and histopathological parameters. 
 
       Glut1 expression 
       =0  1-3 
      n n(%)  n(%) 
Histology  epithelioid  77 44(57%) 33 (43%)  
   sarcomatoid  8 5(62.5%) 3(37.5%) 
p=0.059  biphasic  56 29(52%) 27(48%) 
 
Tumor stage pT1   11 7(63.5%) 4(36.5%) 
   pT2   44 27(61%) 17(39%) 
   pT3   53 22(41.5%) 31(58.5%) 
p=0.027  pT4   20 10(50%) 10(50%) 
 
IMIG stage  1   10 8(80%) 2(20%) 
   2   29 19(65.5%) 10(34.5%) 
   3   71 37(52%) 34(48%) 
p=0.012  4   21 10(47.5%) 11(52.5%)  
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5. Discussion 
 
5.1 Hif1 expression and glycolytic phenotype in human cancers 
 
It has been shown that Hif1 is overexpressed in many human cancers 
(Zhong et al., 1999) and linked to higher mortality in a wide variety of human 
cancers (Aebersold et al., 2001; Bachtiary et al., 2003; Birner et al., 2000; 
Burri et al., 2003; Dales et al., 2005; Generali et al., 2006; Giatromanolaki et 
al., 2004; Giatromanolaki et al., 2001; Giatromanolaki et al., 2003; 
Korkolopoulou et al., 2004; Kronblad et al., 2006; Rajaganeshan et al., 2008; 
Rasheed et al., 2009; Sivridis et al., 2002; Theodoropoulos et al., 2005; 
Theodoropoulos et al., 2004; Trastour et al., 2007; Tzao et al., 2008; Vleugel 
et al., 2005; Yamamoto et al., 2008). The transcription factor Hif1 leads to 
the expression of genes involved in glycolysis and angiogenesis, both of 
which can be seen as hallmarks of cancer (Gatenby and Gillies, 2004). There 
is some weak evidence that overexpression of Hif1 and glycolytic genes like 
Glut1 could also play a role in the pathogenesis of MPM and that the Hif1 
stabilization in mesothelioma cells could be linked to asbestos fibres that are 
deposited in the pleural lining (Riganti et al., 2008; Sekido, 2010; Singhal et 
al., 2003). However in a small study on biopsy samples from 45 patients with 
a malignant pleural mesothelioma no prognostic significance of Hif1 on 
patient survival could be observed (Klabatsa et al., 2006).  
 
 
 
5.2 TMAs for analysis of molecular tumor markers 
 
To analyze a larger patient cohort we used a tissue microarray (TMA) based 
approach and constructed 4 TMAs with samples of pre- and post-
chemotherapy specimens of 192 patients. A TMA allows an efficient analysis 
of molecular markers in human malignant tumors. So that it is possible to 
compare the immunohistochemical staining for a protein on a large number of 
patient samples on one slide. This does not only have the advantage that it 
safes costs but also the conditions for the immunohistochemical staining is 
identical for all tissue samples. A limitation of this technique is that the small 
core diameter might not be representative for an entire tumor (Shergill et al., 
2004). However excellent correlations have been reported between data 
obtained from TMA compared to whole section immunostaining in a wide 
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range of human tumors (Hoos et al., 2001; Mucci et al., 2000; Nocito et al., 
2001; Rubin et al., 2002; Zhang et al., 2003). 
To limit the possible effect of different protein expression in different regions 
of the tumor we used 2 punch cores in the pre-chemotherapy biopsies and 4 
in the pleuro-pneumonectomy specimens. 
To get a patient sample that is large enough for a rare disease like MPM we 
included all patients operated at the University hospital of Zurich since 1999. 
Many of them got their diagnosis at another hospital somewhere else in 
Switzerland or even in Italy (see Table 1). The large distribution of the 
hospitals where the patients got their diagnosis, made it difficult to obtain the 
complete clinical information and the tissue samples needed to construct the 
TMAs. This may also explain the high number of patients excluded from either 
the pre- or post-chemotherapy analysis. 
 
 
 
5.3 Higher Hif1 expression is associated with poorer patient 
survival in the pre-chemotherapy samples and higher Glut1 
expression with advanced tumor stages 
 
The results of our study showed a significant effect towards poorer survival of 
the patients with detectable Hif1 levels, but only in the pre-chemotherapy 
samples. Although a trend towards dismal survival of patients with Hif1 
expression was also visible in the post-chemotherapy samples (Figure 8) it 
was not statistically significant. Interestingly there was a trend to lower Hif1 
protein levels in more advanced stages. Albeit this was only statistically 
significant for T stages, this finding is very surprising. It may be explained by 
general progressive genomic instability of MPM during tumor enlargement. 
Further, histotype and chemotherapy may be relevant influencing factors. 
To further investigate the role of Hif1 and the consequent glycolytic 
phenotype in MPM we stained the 4 TMAs for one of the most important Hif-
target genes: Glucose transporter 1. Neither for the pre- nor the post-
chemotherapy samples we could find a statistically significant correlation 
between patient survival and Glut1 expression. A weak trend towards poorer 
survival of patients with higher Glut1 expression however is visible (Figure 
9,10). We could also observe a statistically significant correlation towards 
higher Glut1 expression in more advanced stages (Table 8). In our patient 
sample there was no correlation between Hif1 and Glut1 expression. This 
surprising finding could be explained by a possible overexpression of the 
second Hif isoform Hif2. A Hif2 staining of the TMAs should be performed 
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in the future to check for a possible correlation between Glut1 and Hif2 
levels. Another explanation could be that the Glut1 expression in MPM is 
more linked to oncogenic signaling via the MAP-Kinase or PI3K mTOR 
pathways. 
One thing that has always to been taken into consideration when working with 
Hif1 is, that it is a very unstable protein and its levels could be affected by 
differences in handling of the tissue. Already during the operation different 
times of malperfusion could affect Hif1 protein levels and consequently the 
levels of its target genes. 
In general, the statistically significant effects towards higher Glut1 expression 
in more advanced stages as well as the poorer survival of patients with Hif1 
protein expression observed add to the evidence that the glycolytic phenotype 
could play a role in the pathogenesis of MPM. In the future it will be very 
important to combine TMA based studies with cell culture experiments and 
exome sequencing of primary tumors. Thereby, it may be possible to further 
elucidate the molecular mechanisms contributing to the changes observed in 
the metabolism of MPM cells. This could possibly lead to the discovery of 
novel therapeutic targets for patients with MPM (Michelakis et al., 2008). 
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